Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.

The data was presented today at an international conference, DNA Vaccines 2012, in San Diego, Ca, by Dr. Christian H. Ottensmeier, MD, PhD, the trial's principal investigator and Professor of Experimental Cancer Research at the University of Southampton, UK. These interim results, from eight patients, are part of a phase II trial that will enroll 31 patients in its chronic myelogenous leukemia (CML) arm. To date, 14 CML patients have been enrolled while another 13 unvaccinated CML patients have been enrolled to serve as a control group. The vaccine has been shown to be safe overall and well-tolerated in the trial subjects. A detailed analysis of T cell immune responses as well as the impact of the vaccination on the molecular marker, BCR-ABL, which is a specific chromosomal abnormality that is associated with chronic myelogenous leukemia (CML) disease, will be performed.

As a result of the favorable safety and immunogenicity profiles observed in the CML vaccinated group, the trial is now open to enroll the acute myeloid leukemia (AML) clinical trial arm, with a total target of 37 subjects in each of the vaccinated and control groups.

This open-label, multi-center phase II clinical trial is evaluating a DNA vaccine-based immune therapy to treat these two types of leukemia. The DNA vaccine, developed by the University of Southampton, is delivered using Inovio's proprietary electroporatio
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million bringing Q3 orders to date to $5 million. The ... America . "We continue to see new ... CEO. "With these orders, our backlog has climbed to over ... BIOREM is a leading clean technology company that designs, manufactures ...
(Date:9/23/2014)... Mass. (PRWEB) September 23, 2014 Cambridge ... by Semantic Web technology, was named in the recent ... Gartner, Inc. , The report details key insights ... , According to Gartner analysts Michael Shanler and ... accelerate innovation activities, expose complex relationships with scientific stakeholders, ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 Dr. ... my third book on healthcare offers a three phase ... 21st century healthcare delivery system that would go far ... state’s responsibility regarding the delivery of healthcare.” , “Every ... safety has failed to provide discernable progress throughout that ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... 3 Human Genome Sciences, Inc. (Nasdaq: HGSI ... 26,697,250 newly issued shares of its common stock at a ... 3,482,250 shares sold upon exercise by the underwriters of their ... the Company from the offering are approximately $356.7 million, after ...
... Aug. 3 Known medically as atopic dermatitis (AD), ... Scratching the affected area of skin may result ... and crusting of the skin.(2) Immuno-modulators called topical calcineurin ... with mild, moderate or severe eczema(3) who fail to ...
... Md., Aug. 3 Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... from the European Medicines Agency (EMEA) for BiTE antibody ... is a novel therapeutic antibody that activates a patient,s ...
Cached Biology Technology:Human Genome Sciences Announces Closing of Public Offering 2Human Genome Sciences Announces Closing of Public Offering 3Five Questions About Protopic (tacrolimus) Ointment 2Five Questions About Protopic (tacrolimus) Ointment 3Five Questions About Protopic (tacrolimus) Ointment 4Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 4
(Date:9/22/2014)... at the University of Chicago have shown that after ... only a handful of pathogenic microbe species remain behind ... and discovered that some can become deadly when provoked ... illness. , The findings, published in mBio , ... Microbiology, may lead to better monitoring and treatment of ...
(Date:9/22/2014)... STATION The smell of cut grass in recent ... signalling distress, but new research says the aroma also ... is need for protection, the plant signals the environment ... recognized as a feeding queue for parasitic wasps to ... lay eggs in the pest insect," said Dr. Michael ...
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2
... While patients hospitalized for a heart attack have long ... analysis by researchers from the Duke Clinical Research Institute ... percent higher risk of dying. , The researchers call ... Meanwhile, they advise cardiologists to begin treatment with sufficient ...
... by fruit fly geneticists for more than a decade ... in mice. , Writing in the May 6 edition ... a streamlined method for creating a "genetic mosaic mouse"--a ... clusters of cells with mutated genes. , The new ...
... statistical method, described in the open-access journal PLoS Biology, ... locations in the genome that influence a particular physical ... by John Storey, Joshua M. Akey, and Leonid Kruglyak, ... them identify all the genomic elements that produce specific ...
Cached Biology News:Morphine for Chest Pain Increases Death Risk 2Morphine for Chest Pain Increases Death Risk 3Mosaic mouse technique offers a powerful new tool to study diseases and genetics 2Mosaic mouse technique offers a powerful new tool to study diseases and genetics 3Improved statistical tools reveal many linked loci 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... real-time PCR detection system uses a fixed ... nm) and a photomultiplier tube for fluorescence ... built on an DNA Engine thermal cycler ... This item includes the thermal cycler, 96-well ...
... The MyiQ detection system is used ... I, FAM, VIC, TET, or JOE fluorophores ... simultaneous collection of fluorescence data from 96 ... quantitation, and customizable end-point analysis. The system ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
Biology Products: